Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around

Description

Summary

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

Official Title

A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation

Keywords

Solid Tumors, Cetuximab, QTX3034

Eligibility

You can join if…

Open to people ages 18 years and up

  • Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic
  • Part 1: - Advanced solid tumors with at least 1 prior systemic therapy
  • Evaluable or Measurable disease per RECIST 1.1.
  • Parts 2 and 3: Measurable disease per RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Adequate organ function

You CAN'T join if...

  • Prior treatment with a KRAS inhibitor
  • Active brain metastases or carcinomatous meningitis
  • History of other malignancy within 2 years
  • Significant cardiovascular disease
  • Disease or disorder that may pose a risk to patient's safety

Other protocol-defined Inclusion/Exclusion Criteria may apply

Locations

  • UCLA Hematology/Oncology not yet accepting patients
    Los Angeles California 90095 United States
  • University of Utah, Huntsman Cancer Center accepting new patients
    Salt Lake City Utah 84112 United States
  • Sarah Cannon Research Institute (SCRI) accepting new patients
    Denver Colorado 80218 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Quanta Therapeutics
ID
NCT06227377
Phase
Phase 1 Solid Tumor Research Study
Study Type
Interventional
Participants
Expecting 250 study participants
Last Updated